These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27190629)

  • 1. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.
    Patel MA; Kim JE; Theodros D; Tam A; Velarde E; Kochel CM; Francica B; Nirschl TR; Ghasemzadeh A; Mathios D; Harris-Bookman S; Jackson CC; Jackson C; Ye X; Tran PT; Tyler B; Coric V; Selby M; Brem H; Drake CG; Pardoll DM; Lim M
    J Immunother Cancer; 2016; 4():28. PubMed ID: 27190629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
    Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
    Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
    Kim YH; Shin SM; Choi BK; Oh HS; Kim CH; Lee SJ; Kim KH; Lee DG; Park SH; Kwon BS
    J Immunol; 2015 Nov; 195(10):4721-9. PubMed ID: 26423152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
    Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
    J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
    Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
    J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
    Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
    J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo.
    Grauer OM; Nierkens S; Bennink E; Toonen LW; Boon L; Wesseling P; Sutmuller RP; Adema GJ
    Int J Cancer; 2007 Jul; 121(1):95-105. PubMed ID: 17315190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-GITR therapy promotes immunity against malignant glioma in a murine model.
    Miska J; Rashidi A; Chang AL; Muroski ME; Han Y; Zhang L; Lesniak MS
    Cancer Immunol Immunother; 2016 Dec; 65(12):1555-1567. PubMed ID: 27734112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid-induced tumour necrosis factor receptor family-related receptor signalling exacerbates hapten-induced colitis by CD4+ T cells.
    Lee SK; Choi BK; Kim YH; Kang WJ; Kim KH; Sakaguchi S; Suh JH; Kim TY; Kwon BS
    Immunology; 2006 Dec; 119(4):479-87. PubMed ID: 17177830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma.
    Kawano M; Tanaka K; Itonaga I; Iwasaki T; Miyazaki M; Ikeda S; Tsumura H
    Oncol Rep; 2015 Oct; 34(4):1995-2001. PubMed ID: 26239052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid-induced TNFR family-related protein (GITR) activation exacerbates murine asthma and collagen-induced arthritis.
    Patel M; Xu D; Kewin P; Choo-Kang B; McSharry C; Thomson NC; Liew FY
    Eur J Immunol; 2005 Dec; 35(12):3581-90. PubMed ID: 16285015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
    Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
    Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma.
    Jahan N; Talat H; Alonso A; Saha D; Curry WT
    Oncoimmunology; 2019; 8(5):e1577108. PubMed ID: 31069135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
    Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
    Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas.
    Amoozgar Z; Kloepper J; Ren J; Tay RE; Kazer SW; Kiner E; Krishnan S; Posada JM; Ghosh M; Mamessier E; Wong C; Ferraro GB; Batista A; Wang N; Badeaux M; Roberge S; Xu L; Huang P; Shalek AK; Fukumura D; Kim HJ; Jain RK
    Nat Commun; 2021 May; 12(1):2582. PubMed ID: 33976133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice.
    Brunn ND; Mauze S; Gu D; Wiswell D; Ueda R; Hodges D; Beebe AM; Zhang S; Escandón E
    J Pharmacol Exp Ther; 2016 Mar; 356(3):574-86. PubMed ID: 26669426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.